Intratympanic gentamicin for MenièRe's disease: A meta-analysis

Laryngoscope

Volumn 114, Issue 12, 2004, Pages 2085-2091

  Cohen Kerem, Raanan ^a   Kisilevsky, Vitaly ^b   Einarson, Thomas R ^c   Kozer, Eran ^a   Koren, Gideon ^a   Rutka, John A ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gentamicin; Intratympanic; Meni re's disease; Meta analysis

Indexed keywords

GENTAMICIN;

CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG INDICATION; FUNCTIONAL ASSESSMENT; HEARING; HUMAN; INNER EAR DISEASE; MEDICAL LITERATURE; MENIERE DISEASE; META ANALYSIS; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VERTIGO; WORD RECOGNITION;

AUDIOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENTAMICINS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MENIERE'S DISEASE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TREATMENT OUTCOME; TYMPANIC MEMBRANE;

EID: 10044298711     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000149439.43478.24     Document Type: Review

References (26)

1. Silverstein H, Lewis WB, Jackson LE, et al. Changing trends in the surgical treatment of Menière's disease: results of a 10-year survey. Ear Nose Throat J 2003;82:185-184.
2. Committee on Hearing and Equilibrium. Report of Subcommittee on Equilibrium and its Measurement. Menière's disease: criteria for diagnosis and evaluation of therapy for reporting. Trans Am Acad Ophthalmol Otolaryngol 1972;76:1462-1464.
3. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg 1995;113:181-185.
4. Pearson BW, Brackmann DE. Committee on Hearing and Equilibrium guidelines for reporting treatment results in Menière's disease. Otolaryngol Head Neck Surg 1985;93:579-581.
5. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-129.
6. Einarson TR. Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example. Clin Ther 1997;19:559-569.
7. Abou-Halawa AS, Poe DS. Efficacy of increased gentamicin concentration for intratympanic injection therapy in Menière's disease. Otol Neurotol 2002;23:494-502.
8. Corsten M, Marsan J, Schramm D, Robichaud J. Treatment of intractable Menière's disease with intratympanic gentamicin: review of the University of Ottawa experience. J Otolaryngol 1997;26:361-364.
9. Harner SG, Driscoll CL, Facer GW, et al. Long-term follow-up of transtympanic gentamicin for Menière's syndrome. Otol Neurotol 2001;22:210-214.
10. Perez N, Martin E, Garcia-Tapia R. Intratympanic gentamicin for intractable Menière's disease. Laryngoscope 2003;113:456-464.
11. Leone CA, Mosca F, Mincione A. Ablation therapy with gentamycin in the treatment of Menière's disease. Acta Otorhinolaryngol Ital 2000;20:322-329.
12. Longridge NS, Mallinson AI. Low-dose intratympanic gentamicin treatment for dizziness in Menière's disease. J Otolaryngol 2000;29:35-39.
13. McFeely WJ, Singleton GT, Rodriguez FJ, Antonelli PJ. Intratympanic gentamicin treatment for Menière's disease. Otolaryngol Head Neck Surg 1998;118:589-596.
14. Kaasinen S, Pyykko I, Ishizaki H, Aalto H. Intratympanic gentamicin in Menière's disease. Acta Otolaryngol 1998;118:294-298.
15. Rauch SD, Oas JG. Intratympanic gentamicin for treatment of intractable Menière's disease: a preliminary report. Laryngoscope 1997;107:49-55.
16. Quaranta A, Aloisi A, De Benedittis G, Scaringi A. Intratympanic therapy for Menière's disease. High-concentration gentamicin with round-window protection. Ann N Y Acad Sci 1999;884:410-424.
17. Quaranta A, Scaringi A, Aloidi A, et al. Intratympanic therapy for Menière's disease: effect of administration of low concentration of gentamicin. Acta Otolaryngol 2001;121:387-392.
18. Atlas JT, Parnes LS. Intratympanic gentamicin titration therapy for intractable Menière's disease. Am J Otol 1999;20:357-363.
19. Kaplan DM, Nedzelski JM, Chen JM, Shipp DB. Intratympanic gentamicin for the treatment of unilateral Menière's disease. Laryngoscope 2000;110:1298-1305.
20. Thorp MA, Shehab ZP, Bance ML, Rutka JA. Does evidence-based medicine exist in the treatment of Menière's disease? A critical review of the last decade of publications. Clin Otolaryngol 2000;25:456-460.
21. Thorp MA, Shehab ZP, Bance ML, Rutka JA. The AAO-HNS Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière's disease: have they been applied in the published literature of the last decade? Clin Otolaryngol 2003;28:173-176.
22. Tran Ba HP, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986;77:1492-1500.
23. Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000;9:1787-1793.
24. Blakley BW. Update on intratympanic gentamicin for Menière's disease. Laryngoscope 2000;110:236-240.
25. Hirsch BE, Kamerer DB. Intratympanic gentamicin therapy for Menière's disease. Am J Otol 1997;18:44-51.
26. Wu IC, Minor LB. Long-term hearing outcome in patients receiving intratympanic gentamicin for Menière's disease. Laryngoscope 2003;113:815-820.